CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.06B, above the global median of $1.18B
- FinancialsAltman Z-Score 9.37: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.06BUSDvs all stocks (USD)
Trailing P/E
82.73xvs Biotechnology peers
Revenue (TTM)
306.30MUSDvs all stocks (USD)
Profit Margin
7.91%vs Biotechnology peers
Beta
1.05xvs all stocks
52-Week Change
26.58%vs all stocks
Market Capitalization
2.06BUSDvs all stocks (USD)
Enterprise Value
1.96BUSDvs all stocks (USD)
Trailing P/E
82.73xvs Biotechnology peers
Forward P/E
46.94xvs Biotechnology peers
PEG Ratio
-0.1655xvs Biotechnology peers
Price to Sales (TTM)
6.64xvs Biotechnology peers
Price to Book (MRQ)
5.49xvs Biotechnology peers
Enterprise to Revenue
6.41xvs Biotechnology peers
Enterprise to EBITDA
63.05xvs Biotechnology peers
Gross Margin
72.82%vs Biotechnology peers
Profit Margin
7.91%vs Biotechnology peers
Operating Margin
0.56%vs Biotechnology peers
Return on Assets (TTM)
2.43%vs Biotechnology peers
Return on Equity (TTM)
7.16%vs Biotechnology peers
Revenue (TTM)
306.30MUSDvs all stocks (USD)
Revenue per Share (TTM)
6.04USDUpdated Sep 28, 2026Quarterly Revenue Growth
22.50%vs Biotechnology peers
Gross Profit (TTM)
228.38MUSDvs all stocks (USD)
EBITDA (TTM)
29.55MUSDvs all stocks (USD)
Net Income (TTM)
24.22MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
22.48%vs Biotechnology peers
Operating Cash Flow (TTM)
69.67MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
55.54MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
276.26MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
70.66MUSDFY2025 · Dec 31, 2025Gross Profit
205.60MUSDFY2025 · Dec 31, 2025Operating Income
11.04MUSDvs all stocks (USD)
Pre-tax Income
17.38MUSDFY2025 · Dec 31, 2025Income Tax Expense
859.00KUSDFY2025 · Dec 31, 2025Net Income
16.52MUSDFY2025 · Dec 31, 2025EBIT
18.01MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
29.55MUSDFY2025 · Dec 31, 2025Research & Development
27.56MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
166.99MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.01MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
630.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
16.52MUSDFY2025 · Dec 31, 2025Operating Cash Flow
48.88MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
100.09MUSDFY2025 · Dec 31, 2025Income Tax Paid
580.00KUSDFY2025 · Dec 31, 2025Interest Paid
489.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
16.52MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.54MUSDFY2025 · Dec 31, 2025Stock-based Compensation
38.77MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.58MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-23.26MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.97MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.24MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-72.37MUSDFY2025 · Dec 31, 2025Sale of Investments
55.60MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-16.77MUSDFY2025 · Dec 31, 2025Other Financing Charges
-6.86MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
7.07MUSDFY2025 · Dec 31, 2025Shares Outstanding
51.17MSharesUpdated Sep 28, 2026Float Shares
50.58MSharesUpdated Sep 28, 2026Shares Short
5.48MSharesUpdated Sep 28, 2026Short Ratio
10.98daysvs all stocks
Short % of Shares Outstanding
13.79%vs all stocks
% Held by Insiders
1.19%vs all stocks
% Held by Institutions
111.04%vs all stocks
Total Cash (MRQ)
162.46MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.17USDUpdated Sep 28, 2026Total Debt (MRQ)
93.13MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2517xvs Biotechnology peers
Current Ratio (MRQ)
5.04xvs Biotechnology peers
Book Value per Share (MRQ)
7.23USDUpdated Sep 28, 2026Total Assets
487.97MUSDvs all stocks (USD)
Total Current Assets
247.44MUSDFY2025 · Dec 31, 2025Total Liabilities
133.33MUSDFY2025 · Dec 31, 2025Total Non-current Assets
240.53MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
84.18MUSDFY2025 · Dec 31, 2025Total Current Liabilities
49.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
100.09MUSDFY2025 · Dec 31, 2025Other Short-term Investments
37.41MUSDFY2025 · Dec 31, 2025Accounts Receivable
84.63MUSDFY2025 · Dec 31, 2025Inventory
17.56MUSDFY2025 · Dec 31, 2025Accounts Payable
15.83MUSDFY2025 · Dec 31, 2025Short-term Debt
14.09MUSDFY2025 · Dec 31, 2025Long-term Debt
82.28MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.90MUSDFY2025 · Dec 31, 2025Common Stock (Book)
730.66MUSDFY2025 · Dec 31, 2025Retained Earnings
-376.30MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
354.64MUSDvs all stocks (USD)
52-Week Low
28.95USDUpdated Sep 28, 202652-Week High
49.32USDUpdated Sep 28, 202652-Week Change
26.58%vs all stocks
Beta
1.05xvs all stocks
50-Day MA
42.69USDUpdated Sep 28, 2026200-Day MA
38.20USDUpdated Sep 28, 2026Avg 10-Day Volume
553.21KSharesUpdated Sep 28, 2026Avg 30-Day Volume
500.44KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
0.4800USDUpdated Sep 28, 2026Other Income / Expense
-44.00KUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.73Profit Margin: 0.08
Financial Health
Altman Z-Score 9.37: safe zoneNotable
Altman Z-Score: 9.37
High earnings qualityNotable
Earnings Quality Score: 2.14
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.06B, above the global median of $1.18BNotable
Market cap (USD): 2,060,554,147Global Median: 1,180,223,658.953
Levered free cash flow is $55.54M, above the global median of $18.73MNotable
Levered free cash flow (USD): 55,544,876Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Alvotech S.A.
Tier 1ProductionApproval-Gated PipelineRule
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Inspire Medical Systems, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sundram Fasteners Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedRevenue Growing With Receivables Growing
Anest Iwata Corporation
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedRevenue Growing With Receivables Growing
Games Workshop Group PLC
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedRevenue Growing With Receivables Growing